Ken Griffin’s Eterna Therapeutics ERNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.58K Buy
+1,323
New +$21.1K ﹤0.01% 12796
2025
Q2
Sell
-175
Closed -$11.7K 13199
2025
Q1
$11.7K Buy
+175
New +$21.6K ﹤0.01% 13478
2024
Q2
Sell
-27
Closed -$24.1K 14539
2024
Q1
$24.1K Buy
+27
New +$18.6K ﹤0.01% 12873
2022
Q4
Sell
-7
Closed -$13K 14986
2022
Q3
$13K Sell
7
-21
-75% -$72.4K ﹤0.01% 12197
2022
Q2
$107K Buy
28
+5
+22% +$35.9K ﹤0.01% 11348
2022
Q1
$349K Buy
23
+7
+44% +$133K ﹤0.01% 10241
2021
Q4
$490K Buy
16
+14
+700% +$761K ﹤0.01% 9745
2021
Q3
$142K Buy
+2
New +$173K ﹤0.01% 12441
2021
Q2
Sell
-3
Closed -$432K 13846
2021
Q1
$85K Buy
3
+2
+200% +$108K ﹤0.01% 12597
2020
Q4
$32K Buy
+1
New +$30.4K ﹤0.01% 10698
2020
Q1
Sell
-1
Closed -$38K 9723
2019
Q4
$38K Buy
+1
New +$42.6K ﹤0.01% 8818
2019
Q3
Sell
-1
Closed -$59K 9303
2019
Q2
$59K Buy
+1
New +$52.4K ﹤0.01% 8677
2018
Q4
Sell
-2
Closed -$110K 9268
2018
Q3
$110K Buy
+2
New +$144K ﹤0.01% 8536
2016
Q1
Hold
0
-$2K 7078
2015
Q4
Hold
0
8574
2015
Q3
Hold
0
8092
2015
Q2
Hold
0
8538
2015
Q1
Hold
0
-$18K 8603
2014
Q4
Hold
0
7890
2014
Q3
Hold
0
7750
2013
Q3
Hold
0
-$12K 6767
2013
Q2
Hold
0
6191

Other funds holding ERNA

Ken Griffin's ERNA Position: Q1 2026 in Review

Ken Griffin opened a new position in Eterna Therapeutics (ERNA) in Q1 2026: 1,323 shares worth $6.58K. The stake represents ﹤0.01% of the portfolio and ranks #12796 among its holdings. This is a return to the name: Ken Griffin previously reported a position in ERNA as recently as Q1 2025.

Ken Griffin first reported a position in ERNA in Q3 2018 and has held it in 13 quarters since. The position peaked at $490K in Q4 2021. 15 funds tracked by Wall St. Rank hold ERNA as of Q1 2026.

  • Ken Griffin held 1,323 shares of Eterna Therapeutics worth $6.58K as of Q1 2026.
  • Eterna Therapeutics was a new Ken Griffin position in Q1 2026.
  • Eterna Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #12796 holding.
  • Ken Griffin first reported a position in Eterna Therapeutics in Q3 2018 and has held it in 13 quarters since.
  • Ken Griffin's Eterna Therapeutics position peaked at $490K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.